AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference

Company Announcement - AIM ImmunoTech Inc. will participate in the Virtual Investor Pitch Conference on June 17, 2024, at 1:00 PM ET, where CEO Thomas K. Equels will present an "elevator pitch" and discuss upcoming milestones [1] - Investors will have the opportunity to submit questions live during the event, and the company aims to address as many as possible within the allotted time [1] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company focused on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [2] - The company's lead product is Ampligen® (rintatolimod), a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator, showing broad-spectrum activity in clinical trials for significant global health issues [2]